Director’s Council of Public Representatives (COPR)
NIH Public Bulletin – January 2010
Leading Medication Development Researcher to Head Drug Discovery Efforts
When: January 19, 2010
Where: Bethesda, MD
Institute: National Institute on Drug Abuse (NIDA)
NIDA announced in January that Phil Skolnick, a leader in corporate and academic drug research, had been appointed Director of NIDA's Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA). Dr. Skolnick is currently a research professor of psychiatry at New York University Langone Medical Center and previously served as Chief Scientific Officer at DOV Pharmaceutical, Inc. At NIDA, he will lead a team that stimulates and conducts all phases of medications development.
For more information about Dr. Skolnick or DPMCDA, please contact the NIDA Press Office at (301) 443-6245 or email@example.com.